Skip to content
Brand AI

Bial

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2016

    BIA 10-2474 first-in-human clinical-trial incident

    A multiple-dose phase-one trial of Bial’s experimental FAAH inhibitor BIA 10-2474, conducted by Biotrial in Rennes, was suspended after the first participant was hospitalized and five participants in total required hospitalization. The first participant later became brain-dead. The incident prompted scrutiny of the trial’s dose escalation, monitoring, sponsor and contract-research-organization responsibilities, and the broader governance of early-stage human drug testing.

    Source